Your current location is：{Current column} >>Text
LinxVista is now insisting I pay a $2,100 “final transaction fee”
{Current column}66People have watched
IntroductionI’ve already followed all the necessary steps, provided the required documents, and my account was a ...
I’ve already followed all the necessary steps,International Trading Platform provided the required documents, and my account was approved weeks ago. But now, they’re introducing this new fee. When I asked for a clear explanation, they just pointed to “regulatory requirements” without offering any documentation. This wasn’t mentioned when I signed up, and it feels like a tactic to delay my withdrawal. Has anyone else encountered this “final transaction fee”?
Tags：
Related articles
China's September export growth hit a five
{Current column}According to the latest data released by China's customs on Monday, China's export growth ...
Read moreAfter coal stocks dropped, they have become attractive.
{Current column}In the Hong Kong stock market, the coal sector continued to decline with several leading stocks fall ...
Read moreGold stocks pressured; China Gold International down nearly 4% on strong dollar and outflows.
{Current column}On Tuesday, the Hong Kong stock market's gold sector continued to decline, impacted by the ongo ...
Read more
Popular Articles
- Geminifin to Apply for FCA License, Expanding UK Presence.
- Barclays: Anticipation of Trump's win drives European stocks to price in impact early.
- 泡泡玛特第三季度的收入大幅增长，推动其股票上涨超过20%，引起了市场的关注
- Ahead of the U.S. election, Asia
- “final payout processing charge”? betalivetradepro forced me to pay this, why?
- Trump’s election prospects lift U.S. stocks, bonds, and oil, boosting market enthusiasm.
Latest articles
-
HorizonCapitalMarket surprised me by introducing a $1,880 “liquidity management charge”
-
Ahead of the U.S. election, Asia
-
Quantum Song stock surged 29%, up 120% YTD, announcing a special dividend for shareholders.
-
Northeast Securities: The domestic dry eye medication market is in its second upgrade
-
The U.S. Justice Department introduces new rules to limit foreign access to sensitive data.
-
AstraZeneca has applied for a new indication listing for its BTK inhibitor, Acalabrutinib, in China.